Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million

ACCESSWIRE09-12

HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2466571712?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/H7HeDNWVDxnQN9797eajOQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/baa49c0054705ac08f97cb63e8f8d24c","is_english":true,"pubTime":"2024-09-12 04:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2466571712","market":"us","top_or_hot":-1,"title":"Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million","media":"ACCESSWIRE","content":"<div>\n<p>HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/champions-oncology-reports-quarterly-revenue-200000263.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Champions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChampions Oncology Reports Quarterly Revenue of $14.1 Million Adjusted EBITDA of $2.0 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-12 04:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/champions-oncology-reports-quarterly-revenue-200000263.html><strong>ACCESSWIRE</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/champions-oncology-reports-quarterly-revenue-200000263.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSBR","symbol_name":"Champions Oncology, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/champions-oncology-reports-quarterly-revenue-200000263.html","article_id":"2466571712","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/H7HeDNWVDxnQN9797eajOQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/baa49c0054705ac08f97cb63e8f8d24c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2466571712","pubTimestamp":1726084800,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. , a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.David Miller, CFO of Champions, added, \"The first quarter saw a return to profitability as revenue increased 12% to $14.1 million while we reduced total costs by more than $2.0 million. The revenue increase, combined with mostly unchanged cost of oncology services, lifted our margin to 50%.\" Miller added, \"While there will be some revenue and margin volatility over the coming quarters, our cost reductions should enable us to remain profitable on an adjusted EBITDA basis.\". Cost of oncology services was $7.1 million for the three-months ended July 31, 2024, a decrease of $612,000, or 8.0% compared to $7.7 million for the three-months ended July 31, 2023. The decrease in cost of oncology services was primarily fro","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSBR":"Champions Oncology, Inc."},"translate_title":"Champions Oncology报告季度收入为1,410万美元，调整后EBITDA为200万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSBR":1},"content_text":"HACKSENSACK, NJ / ACCESSWIRE / September 11, 2024 / Champions Oncology, Inc. (NASDAQ:CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, today announced its financial results for its first quarter of fiscal 2025, ended July 31, 2024.\nFirst Quarter Highlights:\n\nTotal revenue increased 12% to $14.1 million\nMargin improved to 50%\nAdjusted EBITDA of $2.0 million\nNet income of $1.3 million\n\nRonnie Morris, CEO of Champions, commented, \"As outlined on our year-end earnings call, we're cautiously optimistic that we've weathered the worst of the business downturn and we're poised to emerge leaner and stronger. Our first quarter's performance provided further evidence that we're on a strategic course to more consistently deliver the results we have been striving to achieve.\" Morris added, \"Our comprehensive platform, unique data, and strong team are the key ingredients for future growth that will drive long-term returns for our shareholders.\"\nDavid Miller, CFO of Champions, added, \"The first quarter saw a return to profitability as revenue increased 12% to $14.1 million while we reduced total costs by more than $2.0 million. The revenue increase, combined with mostly unchanged cost of oncology services, lifted our margin to 50%.\" Miller added, \"While there will be some revenue and margin volatility over the coming quarters, our cost reductions should enable us to remain profitable on an adjusted EBITDA basis.\"\nFirst Fiscal Quarter Financial Results\nTotal revenue for the first quarter of fiscal 2025 was $14.1 million compared to $12.6 million for the same period last year, an increase of 12%. Operational improvements and efficiencies implemented in the prior year led to an increase in our bookings to revenue conversion percentage contributing to the revenue growth. Total costs and operating expenses for the first quarter of fiscal 2025 were $12.7 million compared to $15.1 million for the first quarter of fiscal 2024, a decrease of $2.4 million or 15.8%.\nFor the first quarter of fiscal 2025, Champions reported income from operations of $1.3 million, including $258,000 in stock-based compensation and $449,000 in depreciation and amortization expenses, compared to a loss from operations of $2.6 million, inclusive of $423,000 in stock-based compensation and $445,000 in depreciation and amortization expenses, in the first quarter of fiscal 2024. Excluding stock-based compensation, depreciation and amortization expenses, Champions reported an adjusted EBITDA income of $2.0 million for the first quarter of fiscal 2025 compared to an adjusted EBITDA loss of $1.7 million in the first quarter of fiscal 2024.\nCost of oncology services was $7.1 million for the three-months ended July 31, 2024, a decrease of $612,000, or 8.0% compared to $7.7 million for the three-months ended July 31, 2023. The decrease in cost of oncology services was primarily from a decline in outsourced lab services. For the three-months ended July 31, 2024, total margin was 49.7% compared to 38.8% for the three-months ended July 31, 2023. The improved margin resulted primarily from a combination of an increase in revenue on a lower cost base due to operational efficiencies implemented and other cost reduction initiatives.\nResearch and development expense for the three-months ended July 31, 2024 was $1.5 million, a decrease of $1.3 million or 47.9%, compared to $2.8 million for the three-months ended July 31, 2023. The decrease was primarily due to reduced investment in research and development, including our target discovery program. Sales and marketing expense for the three-months ended July 31, 2024 was $1.7 million, a slight decrease of $17,000, or 1.0%, compared to $1.7 million for the three-months ended July 31, 2023. General and administrative expense for the three-months ended July 31, 2024 was $2.5 million, a decrease of $413,000, or 14.0%, compared to $2.9 million for the three-months ended July 31, 2023. The decrease was primarily from a reduction in compensation and recruitment expenses.\nNet cash provided by operating activities was approximately $311,000 for the three-months ended July 31, 2024 and was primarily due to our operational income, offset by net changes in our working capital accounts in the ordinary course of business. There were no investing activities for the first quarter of fiscal 2025. Net cash used in financing activities for the three-months ended July 31, 2024 was approximately $37,000 resulting from financing lease payments.\nThe Company ended the quarter with cash on hand of approximately $2.9 million. The Company has no debt.\nConference Call Information:\nThe Company will host a conference call today at 4:30 p.m. EDT (1:30 p.m. PDT) to discuss its first quarter financial results. To participate in the call, please call 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 726315, or provide the verbal reference \"Champions Oncology\".\nFull details of the Company's financial results will be available by or before September 16, 2024 in the Company's Form 10-Q atwww.championsoncology.com.\n* Non-GAAP Financial Information\nSee the attached Reconciliation of GAAP net income (loss) to Non-GAAP net income (loss) for an explanation of the amounts excluded to arrive at Non-GAAP net income (loss) and related Non-GAAP income (loss) per share amounts for the three months ended July 31, 2024 and 2023. Non-GAAP financial measures provide investors and management with supplemental measures of operating performance and trends that facilitate comparisons between periods before and after certain items that would not otherwise be apparent on a GAAP basis. Certain unusual or non-recurring items that management does not believe affect the Company's basic operations do not meet the GAAP definition of unusual or non-recurring items. Non-GAAP net income (loss) and Non-GAAP income (loss) per share are not, and should not, be viewed as a substitute for similar GAAP items. Champions defines Non-GAAP dilutive income (loss) per share amounts as Non-GAAP net income (loss) divided by the weighted average number of diluted shares outstanding. Champions' definition of Non-GAAP net income (loss) and Non-GAAP diluted income (loss) per share may differ from similarly named measures used by other companies and may not be applicable for the current reporting period.\nAbout Champions Oncology, Inc.\nChampions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.\nThis press release may contain \"forward-looking statements\" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Oncology generally uses words such as \"believe,\" \"may,\" \"could,\" \"will,\" \"intend,\" \"expect,\" \"anticipate,\" \"plan,\" and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Oncology's Form 10-K for the fiscal year ended April 30, 2024 for a discussion of such risks, uncertainties and other factors. Although the Company believes the expectations reflected in the forward-looking statements are reasonable, they relate only to events as of the date on which the statements are made, and Champions Oncology's future results, levels of activity, performance or achievements may not meet these expectations. The Company does not intend to update any of the forward-looking statements after the date of this press release to conform these statements to actual results or to changes in Champions Oncology's expectations, except as required by law.\nChampions Oncology, Inc.(Dollars in thousands)\nReconciliation of GAAP to Non-GAAP Net Income (Loss) (Unaudited)\n\n\n\n\n\n\n\n\n\n\nThree Months Ended\n\n\nJuly 31,\n\n\n\n\n\n\n\n\n2024\n\n\n2023\n\n\n\n\n\nNet income (loss) - GAAP\n\n\n$\n1,313\n\n\n$\n(2,566\n)\n\n\n\n\nLess:\n\n\n\n\n\n\n\n\n\n\n\n\n\nStock-based compensation\n\n\n\n258\n\n\n\n423\n\n\n\n\n\nNet income (loss) - Non-GAAP\n\n\n$\n1,571\n\n\n$\n(2,143\n)\n\n\n\n\nReconciliation of GAAP EPS to Non-GAAP EPS (Unaudited)\n\n\n\n\n\n\n\n\n\n\nThree Months Ended\n\n\nJuly 31,\n\n\n\n\n\n\n\n\n2024\n\n\n2023\n\n\n\n\n\nEPS - GAAP, basic\n\n\n$\n0.10\n\n\n$\n(0.19\n)\n\n\n\n\nLess:\n\n\n\n\n\n\n\n\n\n\n\n\n\nEffect of stock-based compensation on EPS\n\n\n\n0.02\n\n\n\n0.03\n\n\n\n\n\nEPS - Non-GAAP, basic\n\n\n$\n0.12\n\n\n$\n(0.16\n)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThree Months Ended\n\n\nJuly 31,\n\n\n\n\n\n\n\n\n2024\n\n\n\n2023\n\n\n\n\n\nEPS - GAAP, diluted\n\n\n$\n0.09\n\n\n$\n(0.19\n)\n\n\n\n\nLess:\n\n\n\n\n\n\n\n\n\n\n\n\n\nEffect of stock-based compensation on EPS\n\n\n\n0.02\n\n\n\n0.03\n\n\n\n\n\nEPS - Non-GAAP, diluted\n\n\n$\n0.11\n\n\n$\n(0.16\n)\n\n\n\n\nUnaudited Condensed Consolidated Statements of Operations (unaudited)\n\n\n\n\n\n\n\n\nThree Months Ended\n\n\nJuly 31,\n\n\n\n\n\n\n\n\n2024\n\n\n2023\n\n\n\n\n\nOncology services revenue\n\n\n$\n14,061\n\n\n$\n12,561\n\n\n\n\n\nCost of oncology services\n\n\n\n7,072\n\n\n\n7,684\n\n\n\n\n\nResearch and development\n\n\n\n1,454\n\n\n\n2,793\n\n\n\n\n\nSales and marketing\n\n\n\n1,679\n\n\n\n1,696\n\n\n\n\n\nGeneral and administrative\n\n\n\n2,527\n\n\n\n2,940\n\n\n\n\n\nIncome (loss) from operations\n\n\n\n1,329\n\n\n\n(2,552\n)\n\n\n\n\nOther income\n\n\n\n5\n\n\n\n14\n\n\n\n\n\nIncome (loss) before provision for income taxes\n\n\n\n1,334\n\n\n\n(2,538\n)\n\n\n\n\nProvision for income taxes\n\n\n\n21\n\n\n\n28\n\n\n\n\n\nNet income (loss)\n\n\n$\n1,313\n\n\n$\n(2,566\n)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNet income (loss) per common share outstanding\n\n\n\n\n\n\n\n\n\n\n\n\n\nbasic\n\n\n$\n0.10\n\n\n$\n(0.19\n)\n\n\n\n\nand diluted\n\n\n$\n0.09\n\n\n$\n(0.19\n)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWeighted average common shares outstanding\n\n\n\n\n\n\n\n\n\n\n\n\n\nbasic\n\n\n\n13,593,766\n\n\n\n13,506,782\n\n\n\n\n\nand diluted\n\n\n\n14,042,379\n\n\n\n13,506,782\n\n\n\n\n\nCondensed Consolidated Balance Sheets\n\n\n\n\n\n\n\n\n\nJuly 31, 2024\n\n\nApril 30, 2024\n\n\n\n\n\n\n\n(unaudited)\n\n\n\n\n\n\n\n\nCash and cash equivalents\n\n\n$\n2,892\n\n\n$\n2,618\n\n\n\n\n\nAccounts receivable, net\n\n\n\n9,032\n\n\n\n9,526\n\n\n\n\n\nOther current assets\n\n\n\n1,254\n\n\n\n1,495\n\n\n\n\n\nTotal current assets\n\n\n\n13,178\n\n\n\n13,639\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nOperating lease right-of-use assets, net\n\n\n\n5,963\n\n\n\n6,252\n\n\n\n\n\nProperty and equipment, net\n\n\n\n5,272\n\n\n\n5,721\n\n\n\n\n\nOther long term assets\n\n\n\n185\n\n\n\n185\n\n\n\n\n\nGoodwill\n\n\n\n335\n\n\n\n335\n\n\n\n\n\nTotal assets\n\n\n$\n24,933\n\n\n$\n26,132\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nAccounts payable and accrued liabilities\n\n\n$\n7,332\n\n\n$\n7,960\n\n\n\n\n\nCurrent portion of operating lease liabilities\n\n\n\n1,369\n\n\n\n1,337\n\n\n\n\n\nOther current liabilities\n\n\n\n151\n\n\n\n150\n\n\n\n\n\nDeferred revenue\n\n\n\n10,312\n\n\n\n12,094\n\n\n\n\n\nTotal current liabilities\n\n\n\n19,164\n\n\n\n21,541\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNon-current operating lease liabilities\n\n\n\n5,738\n\n\n\n6,093\n\n\n\n\n\nOther Non-current Liability\n\n\n\n363\n\n\n\n401\n\n\n\n\n\nTotal liabilities\n\n\n\n25,265\n\n\n\n28,035\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nStockholders' equity (deficit)\n\n\n\n(332\n)\n\n\n(1,903\n)\n\n\n\n\nTotal liabilities and stockholders' equity (deficit)\n\n\n$\n24,933\n\n\n$\n26,132\n\n\n\n\n\n\nUnaudited Condensed Consolidated Statements of Cash Flows (unaudited)\n\n\n\n\n\n\n\n\nThree Months EndedJuly 31,\n\n\n\n\n\n\n\n2024\n\n\n2023\n\n\n\n\n\nCash flows from operating activities:\n\n\n\n\n\n\n\n\n\n\n\nNet income (loss)\n\n\n$\n1,313\n\n\n$\n(2,566\n)\n\n\n\n\nAdjustments to reconcile net income (loss) to net cash provided by (used in) operations:\n\n\n\n\n\n\n\n\n\n\n\n\n\nStock-based compensation expense\n\n\n\n258\n\n\n\n423\n\n\n\n\n\nOperating lease right-of use assets\n\n\n\n289\n\n\n\n270\n\n\n\n\n\nDepreciation and amortization expense\n\n\n\n449\n\n\n\n445\n\n\n\n\n\nAllowance for doubtful accounts and estimated credit losses\n\n\n\n(71\n)\n\n\n162\n\n\n\n\n\nChanges in operating assets and liabilities\n\n\n\n(1,927\n)\n\n\n(2,725\n)\n\n\n\n\nNet cash provided by (used in) operating activities\n\n\n\n311\n\n\n\n(3,991\n)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCash flows from investing activities:\n\n\n\n\n\n\n\n\n\n\n\n\n\nPurchases of property and equipment\n\n\n\n-\n\n\n\n(668\n)\n\n\n\n\nNet cash used in investing activities:\n\n\n\n-\n\n\n\n(668\n)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCash flows from financing activities:\n\n\n\n\n\n\n\n\n\n\n\n\n\nRepurchases of common stock\n\n\n\n-\n\n\n\n(602\n)\n\n\n\n\nProceeds from the exercise of stock options\n\n\n\n-\n\n\n\n12\n\n\n\n\n\nFinance lease payments\n\n\n\n(37\n)\n\n\n-\n\n\n\n\n\nNet cash used in financing activities:\n\n\n\n(37\n)\n\n\n(590\n)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nNet increase (decrease) in cash\n\n\n\n274\n\n\n\n(5,249\n)\n\n\n\n\nCash at beginning of period\n\n\n\n2,618\n\n\n\n10,118\n\n\n\n\n\nCash at the end of period\n\n\n$\n2,892\n\n\n$\n4,869\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSOURCE: Champions Oncology, Inc.\n\nView the original \npress release on accesswire.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2466571712"}